Overview

Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents

Status:
Not yet recruiting

Trial end date:
2026-05-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of a pilot study is to test a study plan to see if it is appropriate for a larger study. This study plan is looking at whether the use of inhaled sedatives (medications that help people be calm and sleep) can reduce delirium (extreme confusion) in children who need a ventilator (breathing machine) compared to IV or oral sedatives. The main question[s] it aims to answer are: - Will people join the study? (recruitment) - Will participants finish the study? - Will healthcare teams accept the study procedures? Participants will be randomized to receive study treatment (inhaled sedation) or standard of care (IV sedation). They will be monitored daily for up to 28 days. They will complete memory, thinking and behaviour tasks after 1 year.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborator:

Canadian Institutes of Health Research (CIHR)

Treatments:

Isoflurane
Sevoflurane

Criteria

Inclusion Criteria:

1. Pediatric patients age from 1 month to less than 18 years who need sedation to
tolerate mechanical ventilation and will remain ventilated for ≥ 24 hours.

2. Receiving IV sedation by infusion or bolus for ≤72h to aid mechanical ventilation (but
will be recruited as early as possible).

Exclusion Criteria:

1. Current use of inhaled prostacyclin (high viscosity of prostacyclin impairs vaporizer
device)

2. Family history or personal history of malignant hyperthermia (MH)

3. Allergy to isoflurane, sevoflurane or other volatile inhaled anesthetic gas

4. Metabolic, mitochondrial or myopathy disease e.g., Duchenne muscular dystrophy
(volatiles may trigger malignant hyperthermia like reaction)

5. Moribund with expected survival < 24h

6. Pregnancy or lactation

7. Suspected or evidence of high intracranial pressure (ICP)